Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

玉峰 席1

  • 1Department of Neonatology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Technology in Cancer Research & Treatment
|July 28, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Technology in cancer research & treatment·2026
Same journal

EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies.

Technology in cancer research & treatment·2026
Same journal

Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.

Technology in cancer research & treatment·2026
Same journal

A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy.

Technology in cancer research & treatment·2026
Same journal

Construction and Clinical Validation of a Colorectal Cancer OPISV Prognostic Model Integrating EPHB2 and ZNF346: Potential Regulatory Role of the Axon Guidance Pathway.

Technology in cancer research & treatment·2026
Same journal

Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma: A Systematic Review of Phase One Clinical Trials.

Technology in cancer research & treatment·2026
See all related articles

Researchers fused human umbilical endothelial cells (HUVECs) with lung cancer cells (A549) to create a novel lung cancer vaccine. This HUVEC-A549 cell line shows promise for inhibiting tumor angiogenesis and stimulating specific anti-tumor immunity.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunology

Background:

  • Human umbilical endothelial cells (HUVECs) demonstrate efficacy in inhibiting tumor angiogenesis.
  • Whole-cell vaccines are being explored for cancer treatment.

Purpose of the Study:

  • To fuse HUVECs with A549 lung adenocarcinoma cells to develop a lung cancer vaccine.
  • To achieve dual effects of inhibiting tumor angiogenesis and inducing specific anti-tumor immunity.

Main Methods:

  • A549 cells were rendered auxotrophic for hypoxanthine guanine phosphoribosyl transferase (HGPRT).
  • Combined electrofusion and polyethylene glycol (PEG) methods were used to fuse HGPRT-auxotrophic A549 cells with HUVECs.
  • Fusion cells were screened using HAT/HT selective media and sorted via flow cytometry to isolate HUVEC-A549 cells.
Keywords:
A549CD31HUVECPEGelectrofusion

Related Experiment Videos

  • Karyotype analysis and western blotting confirmed the identity of HUVEC-A549 cells.

    • Main Results:

    • The combined electrofusion-PEG method yielded a significantly higher fusion efficiency (43.0%) compared to individual methods.
    • Post-screening and sorting, HUVEC-A549 cells constituted 71.2% ± 3.2% of the population.
    • HUVEC-A549 cells exhibited a triploid chromosome mode of 68.
    • Key endothelial markers (VE-cadherin, CD31) were highly expressed in HUVEC-A549 cells, confirming retained HUVEC characteristics.

    Conclusions:

    • The generated HUVEC-A549 cells retain biological characteristics of both parent cell types.
    • This novel cell line holds potential for experimental lung cancer vaccine development.
    • The HUVEC-A549 cell line may offer a dual therapeutic strategy targeting angiogenesis and tumor immunity.